Standard

Анализ показателей выживаемости и оценка факторов прогноза у больных с метастазами рака почки в костях. / Семенов, Дмитрий Владимирович; Орлова, Рашида Вахидовна (Editor); Широкорад, Валерий Иванович (Editor); Кострицкий, Станислав Викторович (Editor).

In: ОНКОУРОЛОГИЯ, Vol. 21, No. 2, 2, 06.08.2025, p. 15-24.

Research output: Contribution to journal › Article

Harvard

Семенов, ДВ, Орлова, РВ (ed.), Широкорад, ВИ (ed.) & Кострицкий, СВ (ed.) 2025, 'Анализ показателей выживаемости и оценка факторов прогноза у больных с метастазами рака почки в костях.', ОНКОУРОЛОГИЯ, vol. 21, no. 2, 2, pp. 15-24. https://doi.org/10.17650/1726-9776-2025-21-2-15-24

APA

Семенов, Д. В., Орлова, Р. В. (Ed.), Широкорад, В. И. (Ed.), & Кострицкий, С. В. (Ed.) (2025). Анализ показателей выживаемости и оценка факторов прогноза у больных с метастазами рака почки в костях. ОНКОУРОЛОГИЯ, 21(2), 15-24. [2]. https://doi.org/10.17650/1726-9776-2025-21-2-15-24

Vancouver

Семенов ДВ, Орлова РВ, (ed.), Широкорад ВИ, (ed.), Кострицкий СВ, (ed.). Анализ показателей выживаемости и оценка факторов прогноза у больных с метастазами рака почки в костях. ОНКОУРОЛОГИЯ. 2025 Aug 6;21(2):15-24. 2. https://doi.org/10.17650/1726-9776-2025-21-2-15-24

Author

Семенов, Дмитрий Владимирович ; Орлова, Рашида Вахидовна (Editor) ; Широкорад, Валерий Иванович (Editor) ; Кострицкий, Станислав Викторович (Editor). / Анализ показателей выживаемости и оценка факторов прогноза у больных с метастазами рака почки в костях. In: ОНКОУРОЛОГИЯ. 2025 ; Vol. 21, No. 2. pp. 15-24.

BibTeX

@article{c5ccbc8bd8e948378d0b80c29c0e5680,
title = "Анализ показателей выживаемости и оценка факторов прогноза у больных с метастазами рака почки в костях.",
abstract = "Background. In patients with bone metastases of renal cell cancer (RCC), the search for new prognostic factors affecting survival rates is necessary. Aim. To analyze survival rates and identify prognostic factors in patients with RCC metastases in the bones. Materials and methods. A retrospective analysis of data of 350 patients with bone metastases of RCC treated at the Moscow City Oncologic Hospital No. 62 and the City Clinical Oncologic Dispensary (Saint Petersburg) from 2006 to 2022 was performed. 117 (33.4 %) patients were classified into the group of intermediate prognosis, 169 (48.3 %) - into the group of poor prognosis. The study investigated clinical and morphologic prognostic factors affecting survival rates in patients with bone metastases of RCC. Statistical analysis was performed using Statistica 10.0 software packages (StatSoft, USA) through construction of Kaplan-Meier curves and survival tables, development of a mathematical model of survival. Results and conclusion. 3-year, 5-year overall survival (OS) of patients with RCC bone metastases was 38 % (95 % confidence interval (CI) 33-44) and 23 % (95 % CI 18-28), respectively, with a median OS of 28.3 months (95 % CI 23.6-32.9) (p",
keywords = "bone metastases, overall survival, prognostic factor, renal cell cancer",
author = "Семенов, {Дмитрий Владимирович} and Орлова, {Рашида Вахидовна} and Широкорад, {Валерий Иванович} and Кострицкий, {Станислав Викторович}",
year = "2025",
month = aug,
day = "6",
doi = "10.17650/1726-9776-2025-21-2-15-24",
language = "русский",
volume = "21",
pages = "15--24",
journal = "Onkourologiya",
issn = "1726-9776",
publisher = "Издательский дом {"}АБВ-пресс{"} ",
number = "2",

}

RIS

TY - JOUR

T1 - Анализ показателей выживаемости и оценка факторов прогноза у больных с метастазами рака почки в костях.

AU - Семенов, Дмитрий Владимирович

A2 - Орлова, Рашида Вахидовна

A2 - Широкорад, Валерий Иванович

A2 - Кострицкий, Станислав Викторович

PY - 2025/8/6

Y1 - 2025/8/6

N2 - Background. In patients with bone metastases of renal cell cancer (RCC), the search for new prognostic factors affecting survival rates is necessary. Aim. To analyze survival rates and identify prognostic factors in patients with RCC metastases in the bones. Materials and methods. A retrospective analysis of data of 350 patients with bone metastases of RCC treated at the Moscow City Oncologic Hospital No. 62 and the City Clinical Oncologic Dispensary (Saint Petersburg) from 2006 to 2022 was performed. 117 (33.4 %) patients were classified into the group of intermediate prognosis, 169 (48.3 %) - into the group of poor prognosis. The study investigated clinical and morphologic prognostic factors affecting survival rates in patients with bone metastases of RCC. Statistical analysis was performed using Statistica 10.0 software packages (StatSoft, USA) through construction of Kaplan-Meier curves and survival tables, development of a mathematical model of survival. Results and conclusion. 3-year, 5-year overall survival (OS) of patients with RCC bone metastases was 38 % (95 % confidence interval (CI) 33-44) and 23 % (95 % CI 18-28), respectively, with a median OS of 28.3 months (95 % CI 23.6-32.9) (p

AB - Background. In patients with bone metastases of renal cell cancer (RCC), the search for new prognostic factors affecting survival rates is necessary. Aim. To analyze survival rates and identify prognostic factors in patients with RCC metastases in the bones. Materials and methods. A retrospective analysis of data of 350 patients with bone metastases of RCC treated at the Moscow City Oncologic Hospital No. 62 and the City Clinical Oncologic Dispensary (Saint Petersburg) from 2006 to 2022 was performed. 117 (33.4 %) patients were classified into the group of intermediate prognosis, 169 (48.3 %) - into the group of poor prognosis. The study investigated clinical and morphologic prognostic factors affecting survival rates in patients with bone metastases of RCC. Statistical analysis was performed using Statistica 10.0 software packages (StatSoft, USA) through construction of Kaplan-Meier curves and survival tables, development of a mathematical model of survival. Results and conclusion. 3-year, 5-year overall survival (OS) of patients with RCC bone metastases was 38 % (95 % confidence interval (CI) 33-44) and 23 % (95 % CI 18-28), respectively, with a median OS of 28.3 months (95 % CI 23.6-32.9) (p

KW - bone metastases

KW - overall survival

KW - prognostic factor

KW - renal cell cancer

UR - https://www.mendeley.com/catalogue/c172c621-1996-3569-ab05-6290d7381586/

U2 - 10.17650/1726-9776-2025-21-2-15-24

DO - 10.17650/1726-9776-2025-21-2-15-24

M3 - статья

VL - 21

SP - 15

EP - 24

JO - Onkourologiya

JF - Onkourologiya

SN - 1726-9776

IS - 2

M1 - 2

ER -

ID: 142462132